ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
Revolution Medicines' drug daraxonrasib has shown significant efficacy in treating metastatic pancreatic cancer, nearly doubling overall survival rates compared to standard chemotherapy. The results from the Phase III RASolute 302 trial were presented at the ASCO26 congress.
Why it matters
This breakthrough represents a major advancement in targeted oncology, potentially changing the standard of care for a historically difficult-to-treat cancer.
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
The report focuses on clinical trial data and medical advancements without promotional bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in